Eli Lilly, Novo Nordisk
Eli Lilly Gets Green Light To Sell Weight-Loss Drug in China
Key Takeaway Eli Lilly announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.Tirzepatide is the active ingredient in Lilly’s injectable diabetes treatment Mounjaro and weight-loss drug Zepbound.
Eli Lilly's weight loss drug tirzepatide gets approval in China
Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Eli Lilly stock soars after Zepbound gets approval in China
Shares of Eli Lilly (LLY) are soaring after the pharmaceutical giant received regulatory approval in China for its GLP-1 weight-loss drug, Zepbound. Senior Reporter Anjalee Khemlani breaks down the approval and why China is a top market for pharmaceutical companies.
Eli Lilly’s stock plunges as investors eye obesity-drug competition
Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers. Lilly’s stock was down more than 7% at midday Thursday — on track for its largest percentage decline since March 2021 — before rebounding slightly.
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE:LLY) Tirzepatide for long-term weight management. It is suitable for long-term weight management of adults whose body mass index (BMI) meets the following requirements based on diet control and increased exercise: ≥28 kg/m2 (obese) or ≥24 kg/m2 (overweight) with at least one condition.
Eli Lilly weight loss drug approved in China
Eli Lilly (LLY) stock rises as Chinese drug regulator approves its weight loss therapy, tirzepatide, for long-term weight management. Read more here.
Eli Lilly's Tirzepatide Gains Chinese Approval, Escalates Competition with Novo Nordisk
Eli Lilly announces that its weight loss drug, tirzepatide, has been approved by Chinese regulators. This move intensifies the company's rivalry with Novo Nordisk in Asia's crucial market. Both firms are ramping up production to meet the growing global demand for weight-loss treatments,
Eli Lilly, Novo Nordisk Shares Fall as Weight-Loss Drug Competition Ramps Up
Shares of drugmakers Eli Lilly and Novo Nordisk continued sinking Thursday on concerns their dominance of the booming anti-obesity drug market is under threat. Shares of Eli Lilly have fallen about 10% over the last two days,
Novo Nordisk, Eli Lilly have strong first-mover advantage in weight loss drug market, analyst says
Emily Field, head of European pharmaceuticals research at Barclays, says it's too early to say what the competitive landscape will look like in five years for the weight loss drug market, as many trials are still in an early stage.
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's ...
24/7 Wall St on MSN23h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart  has been straight up and to the right, up 553% and ...
Eli Lilly, Novo slip as Roche posts early-stage data for oral weight loss drug
Eli Lilly (LLY) and Novo Nordisk (NVO) under pressure as Roche (RHHBY) posts early-stage data for oral weight loss drug ...
Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced ...
3M Co. stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
FierceBiotech12h
Morphic kept it simple in M&A maneuvers, staying focused on Lilly to reel in $3.2B buyout
Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion ...
Eli Lilly, Novo extend muti-day decline in rare selloff
Shares of weight loss drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) extended a multi-day decline on Thursday, losing ...
Morningstar1d
Eli Lilly on Pace for Largest Percent Decrease Since September 2021 — Data Talk
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.